Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons

Published:2024-08 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Garcia Christine,Abrahami Devin,Polli Anna,Chu Haitao,Chandler Conor,Tan Min,Kelton John Mark,Thomaidou Despina,Bauer Todd

Funder

Pfizer

Publisher

Elsevier BV

Reference34 articles.

1. Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology;Ettinger;J Nat Comp Cancer Net,2022

2. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study;Mok;Ann Oncol,2020

3. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

4. Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial;Camidge;J Thorac Oncol,2021

5. Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic alk–inhibitor-naive alk+ non–small cell lung cancer: final results from the phase III ALTA-1L study;Ahn;Clin Lung Cancer,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP